Upadacitinib Treats Moderate-to-Severe Atopic Dermatitis

FRIDAY, May 21, 2021 -- Upadacitinib shows short-term efficacy for moderate-to-severe atopic dermatitis in adolescents and adults, according to a study published online May 20 in The Lancet. Emma Guttman-Yassky, M.D., from the Icahn School of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news